Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 117 articles:
HTML format



Single Articles


    April 2021
  1. PHAM LV, Pedersen MS, Fahnoe U, Fernandez-Antunez C, et al
    HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4.
    Gut. 2021 Apr 8. pii: gutjnl-2020-323585. doi: 10.1136/gutjnl-2020-323585.
    PubMed     Abstract available


    March 2021
  2. PAN CQ, Dai E, Duan Z, Han G, et al
    Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China.
    Gut. 2021 Mar 31. pii: gutjnl-2020-322719. doi: 10.1136/gutjnl-2020-322719.
    PubMed     Abstract available


  3. YUEN MF, Wong DK, Schluep T, Lai CL, et al
    Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment.
    Gut. 2021 Mar 12. pii: gutjnl-2020-323445. doi: 10.1136/gutjnl-2020-323445.
    PubMed     Abstract available


    February 2021
  4. PENEAU C, Imbeaud S, La Bella T, Hirsch TZ, et al
    Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma.
    Gut. 2021 Feb 9. pii: gutjnl-2020-323153. doi: 10.1136/gutjnl-2020-323153.
    PubMed     Abstract available


    January 2021
  5. BUKH J
    Vaccines against hepatitis C: a travel into neutralisation space.
    Gut. 2021 Jan 25. pii: gutjnl-2020-323377. doi: 10.1136/gutjnl-2020-323377.
    PubMed    


  6. LIU CH, Chen CY, Su WW, Tseng KC, et al
    Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.
    Gut. 2021 Jan 6. pii: gutjnl-2020-323569. doi: 10.1136/gutjnl-2020-323569.
    PubMed     Abstract available


    December 2020
  7. SVICHER V, Salpini R, Piermatteo L, Carioti L, et al
    Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B.
    Gut. 2020 Dec 21. pii: gutjnl-2020-323300. doi: 10.1136/gutjnl-2020-323300.
    PubMed     Abstract available


  8. BANKWITZ D, Bahai A, Labuhn M, Doepke M, et al
    Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies.
    Gut. 2020 Dec 15. pii: gutjnl-2020-321190. doi: 10.1136/gutjnl-2020-321190.
    PubMed     Abstract available


  9. YU ML, Huang CF, Wei YJ, Lin WY, et al
    Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
    Gut. 2020 Dec 10. pii: gutjnl-2020-323277. doi: 10.1136/gutjnl-2020-323277.
    PubMed     Abstract available


  10. SONG S, Shi Y, Wu W, Wu H, et al
    Reticulon 3-mediated Chk2/p53 activation suppresses hepatocellular carcinogenesis and is blocked by hepatitis B virus.
    Gut. 2020 Dec 10. pii: gutjnl-2020-321386. doi: 10.1136/gutjnl-2020-321386.
    PubMed     Abstract available


    November 2020
  11. KIM HL, Kim GA, Park JA, Kang HR, et al
    Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.
    Gut. 2020 Nov 25. pii: gutjnl-2020-321309. doi: 10.1136/gutjnl-2020-321309.
    PubMed     Abstract available


  12. TAKEUCHI M, Vidigal PT, Guerra MT, Hundt MA, et al
    Neutrophils interact with cholangiocytes to cause cholestatic changes in alcoholic hepatitis.
    Gut. 2020 Nov 19. pii: gutjnl-2020-322540. doi: 10.1136/gutjnl-2020-322540.
    PubMed     Abstract available


  13. ZENG G, Gill US, Kennedy PTF
    Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis.
    Gut. 2020;69:1907-1912.
    PubMed    


    October 2020
  14. CASTRY M, Cousien A, Supervie V, Velter A, et al
    Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach.
    Gut. 2020 Oct 27. pii: gutjnl-2020-321744. doi: 10.1136/gutjnl-2020-321744.
    PubMed     Abstract available


    September 2020
  15. LIU K, Peng P, Cai F, Huang J, et al
    Comparison of the long-term efficacy between tenofovir and entecavir in chronic hepatitis B patients.
    Gut. 2020 Sep 14. pii: gutjnl-2020-322642. doi: 10.1136/gutjnl-2020-322642.
    PubMed    


    August 2020
  16. SETO WK, Liu KS, Mak LY, Cloherty G, et al
    Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation.
    Gut. 2020 Aug 5. pii: gutjnl-2020-321116. doi: 10.1136/gutjnl-2020-321116.
    PubMed     Abstract available


    July 2020
  17. HOFMANN M, Thimme R
    Hepatitis B vaccine and NK cells: a new player in memory.
    Gut. 2020 Jul 15. pii: gutjnl-2020-321151. doi: 10.1136/gutjnl-2020-321151.
    PubMed    


    June 2020
  18. CARGILL Z, Brown SE, Dusheiko G, Agarwal K, et al
    Risk stratification in chronic hepatitis B patients for hepatocellular carcinoma surveillance: management in migrant sub-Saharan African populations.
    Gut. 2020 Jun 30. pii: gutjnl-2020-322181. doi: 10.1136/gutjnl-2020-322181.
    PubMed    


  19. ZOLDAN K, Hofmann M
    B protected: from vertical HCV transmission?
    Gut. 2020 Jun 30. pii: gutjnl-2020-321364. doi: 10.1136/gutjnl-2020-321364.
    PubMed    


  20. HORVATITS T, Varwig-Janssen D, Schulze Zur Wiesch J, Lubke R, et al
    No link between male infertility and HEV genotype 3 infection.
    Gut. 2020;69:1150-1151.
    PubMed    


    April 2020
  21. DE JONG YP, Liang TJ
    Stem cell-derived HCV infection systems illustrate the bright future of human hepatocyte research.
    Gut. 2020 Apr 29. pii: gutjnl-2020-321216. doi: 10.1136/gutjnl-2020-321216.
    PubMed    


  22. LUTCKII A, Strunz B, Zhirkov A, Filipovich O, et al
    Evidence for B cell maturation but not trained immunity in uninfected infants exposed to hepatitis C virus.
    Gut. 2020 Apr 27. pii: gutjnl-2019-320269. doi: 10.1136/gutjnl-2019-320269.
    PubMed     Abstract available


    March 2020
  23. SU F, Ioannou GN, Berry K
    No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
    Gut. 2020 Mar 30. pii: gutjnl-2019-319867. doi: 10.1136/gutjnl-2019-319867.
    PubMed     Abstract available


  24. HUTCHINSON SJ, Valerio H, McDonald SA, Yeung A, et al
    Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
    Gut. 2020 Mar 26. pii: gutjnl-2019-320007. doi: 10.1136/gutjnl-2019-320007.
    PubMed     Abstract available


  25. YOUNOSSI ZM, Stepanova M, Younossi Y, Golabi P, et al
    Epidemiology of chronic liver diseases in the USA in the past three decades.
    Gut. 2020;69:564-568.
    PubMed     Abstract available


    February 2020
  26. SALERNO D, Chiodo L, Alfano V, Floriot O, et al
    Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription.
    Gut. 2020 Feb 29. pii: gutjnl-2019-319637. doi: 10.1136/gutjnl-2019-319637.
    PubMed     Abstract available


  27. CARPENTIER A, Sheldon J, Vondran FWR, Brown RJ, et al
    Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus.
    Gut. 2020 Feb 29. pii: gutjnl-2019-319354. doi: 10.1136/gutjnl-2019-319354.
    PubMed     Abstract available


  28. BOYD A, Wandeler G
    Hepatitis D virus: is it all in the family?
    Gut. 2020 Feb 14. pii: gutjnl-2019-320549. doi: 10.1136/gutjnl-2019-320549.
    PubMed    


  29. KAMAL F, Khan MA, Ahmed A, Nair S, et al
    Tenofovir versus entecavir in prevention of hepatocellular carcinoma and mortality in patients with chronic hepatitis B.
    Gut. 2020 Feb 10. pii: gutjnl-2019-320554. doi: 10.1136/gutjnl-2019-320554.
    PubMed    


    January 2020
  30. DOLMAN GE, Kennedy PTF
    Hepatitis B reactivation: reducing the risk in patients with inflammatory bowel disease.
    Gut. 2020 Jan 30. pii: gutjnl-2019-319480. doi: 10.1136/gutjnl-2019-319480.
    PubMed    


  31. OECHSLIN N, Moradpour D, Gouttenoire J
    Hepatitis E virus finds its path through the gut.
    Gut. 2020 Jan 8. pii: gutjnl-2019-320206. doi: 10.1136/gutjnl-2019-320206.
    PubMed    


  32. BESOMBES C, Njouom R, Paireau J, Lachenal G, et al
    The epidemiology of hepatitis delta virus infection in Cameroon.
    Gut. 2020 Jan 6. pii: gutjnl-2019-320027. doi: 10.1136/gutjnl-2019-320027.
    PubMed     Abstract available


  33. ZHUANG Y, Xu HC, Shinde PV, Warfsmann J, et al
    Fragile X mental retardation protein protects against tumour necrosis factor-mediated cell death and liver injury.
    Gut. 2020;69:133-145.
    PubMed     Abstract available


  34. VERRIER ER, Weiss A, Bach C, Heydmann L, et al
    Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets.
    Gut. 2020;69:158-167.
    PubMed     Abstract available


    December 2019
  35. TENG YX, Li MJ, Xiang BD, Zhong JH, et al
    Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis.
    Gut. 2019 Dec 16. pii: gutjnl-2019-320326. doi: 10.1136/gutjnl-2019-320326.
    PubMed    


    November 2019
  36. LIAW YF, Jeng WJ
    Benefit of stopping finite nucleos(t)ide analogues therapy in chronic hepatitis B patients.
    Gut. 2019 Nov 29. pii: gutjnl-2019-320341. doi: 10.1136/gutjnl-2019-320341.
    PubMed    


  37. MARION O, Lhomme S, Nayrac M, Dubois M, et al
    Hepatitis E virus replication in human intestinal cells.
    Gut. 2019 Nov 14. pii: gutjnl-2019-319004. doi: 10.1136/gutjnl-2019-319004.
    PubMed     Abstract available


  38. SHEN DT, Goyal H, Xu HG
    Differences in delta virus hepatitis diagnosis methods and its effect on the hepatitis D prevalence.
    Gut. 2019 Nov 12. pii: gutjnl-2019-320159. doi: 10.1136/gutjnl-2019-320159.
    PubMed    


  39. ZHAO HJ, Han QJ, Wang G, Lin A, et al
    Poly I:C-based rHBVvac therapeutic vaccine eliminates HBV via generation of HBV-specific CD8(+) effector memory T cells.
    Gut. 2019;68:2032-2043.
    PubMed     Abstract available


    October 2019
  40. LEE SW, Kwon JH, Lee HL, Yoo SH, et al
    Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
    Gut. 2019 Oct 31. pii: gutjnl-2019-318947. doi: 10.1136/gutjnl-2019-318947.
    PubMed     Abstract available


  41. GAVRIC A, Dezman R, Rankovic B, Ribnikar M, et al
    Nutmeg liver, fever and elevated liver enzymes in a young man.
    Gut. 2019;68:1773-1837.
    PubMed    


    September 2019
  42. KAO JH, Berg T
    Nucleos(t)ide analogues in patients with chronic hepatitis B: to stop or not to stop?
    Gut. 2019 Sep 16. pii: gutjnl-2019-319648. doi: 10.1136/gutjnl-2019-319648.
    PubMed    


    August 2019
  43. LIEM KS, Fung S, Wong DK, Yim C, et al
    Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
    Gut. 2019 Aug 28. pii: gutjnl-2019-318981. doi: 10.1136/gutjnl-2019-318981.
    PubMed     Abstract available


  44. XIAO Y, Sun K, Duan Z, Liu Z, et al
    Quasispecies characteristic in "a" determinant region is a potential predictor for the risk of immunoprophylaxis failure of mother-to-child-transmission of sub-genotype C2 hepatitis B virus: a prospective nested case-control study.
    Gut. 2019 Aug 24. pii: gutjnl-2019-318278. doi: 10.1136/gutjnl-2019-318278.
    PubMed     Abstract available


    June 2019
  45. WANG L, Zhang Z, Shu J, Zhang H, et al
    Absence of hepatitis E virus RNA in semen samples of infertile male in China.
    Gut. 2019 Jun 19. pii: gutjnl-2019-319234. doi: 10.1136/gutjnl-2019-319234.
    PubMed    


  46. WEI Y, Li Y, Yan L, Sun C, et al
    Alterations of gut microbiome in autoimmune hepatitis.
    Gut. 2019 Jun 14. pii: gutjnl-2018-317836. doi: 10.1136/gutjnl-2018-317836.
    PubMed     Abstract available


    May 2019
  47. HERZOG K, Bandiera S, Pernot S, Fauvelle C, et al
    Functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity.
    Gut. 2019 May 10. pii: gutjnl-2018-317423. doi: 10.1136/gutjnl-2018-317423.
    PubMed     Abstract available


  48. FAN C, Li M, Gan Y, Chen T, et al
    A simple AGED score for risk classification of primary liver cancer: development and validation with long-term prospective HBsAg-positive cohorts in Qidong, China.
    Gut. 2019;68:948-949.
    PubMed    


  49. SCHUCH A, Salimi Alizei E, Heim K, Wieland D, et al
    Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load.
    Gut. 2019;68:905-915.
    PubMed     Abstract available


  50. HOOGEVEEN RC, Robidoux MP, Schwarz T, Heydmann L, et al
    Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection.
    Gut. 2019;68:893-904.
    PubMed     Abstract available


    April 2019
  51. SHEN DT, Ji DZ, Chen HY, Goyal H, et al
    Hepatitis D: not a rare disease anymore: global update for 2017-2018.
    Gut. 2019 Apr 9. pii: gutjnl-2019-318691. doi: 10.1136/gutjnl-2019-318691.
    PubMed    


    March 2019
  52. ZHANG TY, Guo XR, Wu YT, Kang XZ, et al
    A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice.
    Gut. 2019 Mar 29. pii: gutjnl-2018-317725. doi: 10.1136/gutjnl-2018-317725.
    PubMed     Abstract available


    February 2019
  53. CANDOTTI D, Assennato SM, Laperche S, Allain JP, et al
    Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose.
    Gut. 2019;68:313-321.
    PubMed     Abstract available


    January 2019
  54. YUAN L, Jiang J, Liu X, Zhang Y, et al
    HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation.
    Gut. 2019 Jan 30. pii: gutjnl-2018-316091. doi: 10.1136/gutjnl-2018-316091.
    PubMed     Abstract available


    December 2018
  55. STOCKDALE AJ, Kreuels B, Henrion MRY, Giorgi E, et al
    Hepatitis D prevalence: problems with extrapolation to global population estimates.
    Gut. 2018 Dec 19. pii: gutjnl-2018-317874. doi: 10.1136/gutjnl-2018-317874.
    PubMed    


    November 2018
  56. GILL US, Pallett LJ, Thomas N, Burton AR, et al
    Fine needle aspirates comprehensively sample intrahepatic immunity.
    Gut. 2018 Nov 28. pii: gutjnl-2018-317071. doi: 10.1136/gutjnl-2018-317071.
    PubMed     Abstract available


  57. LI H, Zhai N, Wang Z, Song H, et al
    Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection.
    Gut. 2018;67:2035-2044.
    PubMed     Abstract available


    October 2018
  58. WEDEMEYER H, Negro F
    Devil hepatitis D: an orphan disease or largely underdiagnosed?
    Gut. 2018 Oct 27. pii: gutjnl-2018-317403. doi: 10.1136/gutjnl-2018-317403.
    PubMed    


  59. YANG HC, Kao JH
    Quantification of HBV core antibodies may help revisit infectious occult hepatitis B virus.
    Gut. 2018 Oct 9. pii: gutjnl-2018-317385. doi: 10.1136/gutjnl-2018-317385.
    PubMed    


  60. LU XJ, Li XH, Yuan ZX, Sun HY, et al
    Assessment of liver fibrosis with the gamma-glutamyl transpeptidase to platelet ratio: a multicentre validation in patients with HBV infection.
    Gut. 2018;67:1903-1904.
    PubMed    


    September 2018
  61. LLIBRE A, Shimakawa Y, Duffy D
    Potential utility of the Genedrive point-of-care test for HCV RNA detection.
    Gut. 2018 Sep 22. pii: gutjnl-2018-317218. doi: 10.1136/gutjnl-2018-317218.
    PubMed    


  62. CHEN HY, Shen DT, Ji DZ, Han PC, et al
    Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis.
    Gut. 2018 Sep 18. pii: gutjnl-2018-316601. doi: 10.1136/gutjnl-2018-316601.
    PubMed     Abstract available


    August 2018
  63. GAO Y, Zhou Z, Ren T, Kim SJ, et al
    Alcohol inhibits T-cell glucose metabolism and hepatitis in ALDH2-deficient mice and humans: roles of acetaldehyde and glucocorticoids.
    Gut. 2018 Aug 18. pii: gutjnl-2018-316221. doi: 10.1136/gutjnl-2018-316221.
    PubMed     Abstract available


  64. LOCARNINI S, Raimondo G
    How infectious is the hepatitis B virus? Readings from the occult.
    Gut. 2018 Aug 1. pii: gutjnl-2018-316900. doi: 10.1136/gutjnl-2018-316900.
    PubMed    


    July 2018
  65. LIM CJ, Lee YH, Pan L, Lai L, et al
    Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
    Gut. 2018 Jul 3. pii: gutjnl-2018-316510. doi: 10.1136/gutjnl-2018-316510.
    PubMed     Abstract available


    June 2018
  66. LEMOINE M, Tillmann HL
    What is required from HCV point-of-care tests to reduce the burden of hepatitis C infection? 'Development and clinical validation of the genedrive point-of-care test for qualitative detection of hepatitis C virus'.
    Gut. 2018 Jun 29. pii: gutjnl-2018-316438. doi: 10.1136/gutjnl-2018-316438.
    PubMed    


  67. NEGRO F
    Expanded benefits of curing the extrahepatic manifestations of HCV infection.
    Gut. 2018 Jun 5. pii: gutjnl-2018-316578. doi: 10.1136/gutjnl-2018-316578.
    PubMed    


    May 2018
  68. WANG K, Lu X, Zhou H, Gao Y, et al
    Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study.
    Gut. 2018 May 5. pii: gutjnl-2018-316204. doi: 10.1136/gutjnl-2018-316204.
    PubMed     Abstract available


  69. BERTOLETTI A, Kennedy PTF, Durantel D
    HBV infection and HCC: the 'dangerous liaisons'.
    Gut. 2018;67:787-788.
    PubMed    


    April 2018
  70. CACOUB P, Desbois AC, Comarmond C, Saadoun D, et al
    Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis.
    Gut. 2018 Apr 27. pii: gutjnl-2018-316234. doi: 10.1136/gutjnl-2018-316234.
    PubMed     Abstract available


  71. SHIHA G, Esmat G, Hassany M, Soliman R, et al
    Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
    Gut. 2018 Apr 17. pii: gutjnl-2017-315906. doi: 10.1136/gutjnl-2017-315906.
    PubMed     Abstract available


  72. LLIBRE A, Shimakawa Y, Mottez E, Ainsworth S, et al
    Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus.
    Gut. 2018 Apr 3. pii: gutjnl-2017-315783. doi: 10.1136/gutjnl-2017-315783.
    PubMed     Abstract available


  73. GILL US, Pallett LJ, Kennedy PTF, Maini MK, et al
    Liver sampling: a vital window into HBV pathogenesis on the path to functional cure.
    Gut. 2018;67:767-775.
    PubMed     Abstract available


  74. TAN W, Xia J, Dan Y, Li M, et al
    Genome-wide association study identi fi es HLA-DR variants conferring risk of HBV-related acute-on-chronic liver failure.
    Gut. 2018;67:757-766.
    PubMed     Abstract available


    March 2018
  75. LIN HH, Tseng TC, Kao JH
    Large and middle hepatitis B surface antigen: the lower the better?
    Gut. 2018 Mar 7. pii: gutjnl-2018-316030. doi: 10.1136/gutjnl-2018-316030.
    PubMed    


    February 2018
  76. HEO MJ, Kim TH, You JS, Blaya D, et al
    Alcohol dysregulates miR-148a in hepatocytes through FoxO1, facilitating pyroptosis via TXNIP overexpression.
    Gut. 2018 Feb 23. pii: gutjnl-2017-315123. doi: 10.1136/gutjnl-2017-315123.
    PubMed     Abstract available


  77. MURATA K, Asano M, Matsumoto A, Sugiyama M, et al
    Induction of IFN-lambda3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
    Gut. 2018;67:362-371.
    PubMed     Abstract available


    January 2018
  78. CHEN CJ
    Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges.
    Gut. 2018 Jan 24. pii: gutjnl-2017-315407. doi: 10.1136/gutjnl-2017-315407.
    PubMed    


  79. IBRAHIM SH, Hirsova P, Gores GJ
    Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.
    Gut. 2018 Jan 24. pii: gutjnl-2017-315691. doi: 10.1136/gutjnl-2017-315691.
    PubMed     Abstract available


  80. YIGIT B, Boyle M, Ozler O, Erden N, et al
    Plasma cell-free DNA methylation: a liquid biomarker of hepatic fibrosis.
    Gut. 2018 Jan 20. pii: gutjnl-2017-315668. doi: 10.1136/gutjnl-2017-315668.
    PubMed    


  81. KIM GA, Lim YS
    Response to: 'Prognosis of immune-tolerant phase chronic hepatitis B' by Chu and Liaw.
    Gut. 2018 Jan 13. pii: gutjnl-2017-315815. doi: 10.1136/gutjnl-2017-315815.
    PubMed    


    December 2017
  82. GIERSCH K, Bhadra OD, Volz T, Allweiss L, et al
    Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo.
    Gut. 2017 Dec 7. pii: gutjnl-2017-314713. doi: 10.1136/gutjnl-2017-314713.
    PubMed     Abstract available


    November 2017
  83. WANG X, Yan Y, Gan T, Yang X, et al
    A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey.
    Gut. 2017 Nov 27. pii: gutjnl-2017-314870. doi: 10.1136/gutjnl-2017-314870.
    PubMed     Abstract available


  84. CHU CM, Liaw YF
    Prognosis of immune-tolerant phase chronic hepatitis B.
    Gut. 2017 Nov 25. pii: gutjnl-2017-315603. doi: 10.1136/gutjnl-2017-315603.
    PubMed    


  85. HILLAIRE S, Kahn JE, Picone O, Cazals-Hatem D, et al
    Rare cause of abdominal pain and fever in a pregnant woman.
    Gut. 2017;66:1911-1982.
    PubMed     Abstract available


    October 2017
  86. KIM GA, Lim YS, Han S, Choi J, et al
    High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
    Gut. 2017 Oct 21. pii: gutjnl-2017-314904. doi: 10.1136/gutjnl-2017-314904.
    PubMed     Abstract available


    September 2017
  87. PFEFFERKORN M, Bohm S, Schott T, Deichsel D, et al
    Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers.
    Gut. 2017 Sep 26. pii: gutjnl-2017-313811. doi: 10.1136/gutjnl-2017-313811.
    PubMed     Abstract available


  88. WU T, Li J, Shao L, Xin J, et al
    Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure.
    Gut. 2017 Sep 19. pii: gutjnl-2017-314641. doi: 10.1136/gutjnl-2017-314641.
    PubMed     Abstract available



  89. Erratum: The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
    Gut. 2017;66:1730.
    PubMed    


    August 2017
  90. HUANG F, Long F, Yu W, Situ J, et al
    High prevalence of hepatitis E virus in semen of infertile male and causes testis damage.
    Gut. 2017 Aug 31. pii: gutjnl-2017-314884. doi: 10.1136/gutjnl-2017-314884.
    PubMed    


  91. ZHANG W, Sun M, Chen G, An Y, et al
    Reassessment of gamma-glutamyl transpeptidase to platelet ratio (GPR): a large-sample, dynamic study based on liver biopsy in a Chinese population with chronic hepatitis B virus (HBV) infection.
    Gut. 2017 Aug 16. pii: gutjnl-2017-313896. doi: 10.1136/gutjnl-2017-313896.
    PubMed    


  92. THOMPSON A, Locarnini S, Revill P
    Reply: 'More viral mutants, less HBsAg clearance? One size may not fit all'.
    Gut. 2017;66:1534-1535.
    PubMed    


    July 2017
  93. PETTA S, Craxi A
    Can we prevent and modify cardiometabolic disorders by controlling HCV infection?
    Gut. 2017 Jul 13. pii: gutjnl-2017-314505. doi: 10.1136/gutjnl-2017-314505.
    PubMed    


  94. NASSAL M
    Chronic hepatitis B: divide and conquer?
    Gut. 2017 Jul 13. pii: gutjnl-2017-314255. doi: 10.1136/gutjnl-2017-314255.
    PubMed    


  95. TSENG TC, Yang HC, Kao JH
    More viral mutants, less HBsAg clearance? One size may not fit all.
    Gut. 2017;66:1349.
    PubMed    


    June 2017
  96. LEVANDER S, Holmstrom F, Frelin L, Ahlen G, et al
    Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model.
    Gut. 2017 Jun 23. pii: gutjnl-2016-313579. doi: 10.1136/gutjnl-2016-313579.
    PubMed     Abstract available


  97. MAHALE P, Engels EA, Li R, Torres HA, et al
    The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
    Gut. 2017 Jun 20. pii: gutjnl-2017-313983. doi: 10.1136/gutjnl-2017-313983.
    PubMed     Abstract available


  98. SUN HY, Cheng PN, Tseng CY, Tsai WJ, et al
    Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.
    Gut. 2017 Jun 14. pii: gutjnl-2017-313832. doi: 10.1136/gutjnl-2017-313832.
    PubMed     Abstract available


  99. SCHIAVON LL, Narciso-Schiavon JL, Ferraz MLG, Silva AEB, et al
    The gamma-glutamyl transpeptidase to platelet ratio (GPR) in HBV patients: just adding up?
    Gut. 2017;66:1169-1170.
    PubMed    


    May 2017
  100. THOMAS E
    Hepatitis B virus X protein: TRIMming antiviral defences in hepatocytes.
    Gut. 2017 May 5. pii: gutjnl-2017-314013. doi: 10.1136/gutjnl-2017-314013.
    PubMed    


    April 2017
  101. ALLWEISS L, Volz T, Giersch K, Kah J, et al
    Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.
    Gut. 2017 Apr 20. pii: gutjnl-2016-312162. doi: 10.1136/gutjnl-2016-312162.
    PubMed     Abstract available


  102. RAMACHANDRAN A, Jaeschke H
    PGAM5: a new player in immune-mediated liver injury.
    Gut. 2017;66:567-568.
    PubMed    


    March 2017
  103. COLPITTS CC, Tawar RG, Mailly L, Thumann C, et al
    Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
    Gut. 2017 Mar 30. pii: gutjnl-2016-312577. doi: 10.1136/gutjnl-2016-312577.
    PubMed     Abstract available


  104. LAURAIN A, Kramer L, Sultanik P, Vallet-Pichard A, et al
    Mortality associated with the treatment of HCV with direct-acting antivirals.
    Gut. 2017 Mar 23. pii: gutjnl-2017-313869. doi: 10.1136/gutjnl-2017-313869.
    PubMed    


  105. HERNAEZ R, Sola E, Moreau R, Gines P, et al
    Acute-on-chronic liver failure: an update.
    Gut. 2017;66:541-553.
    PubMed     Abstract available


    February 2017
  106. ARNOLD F, Patch D, Yu D, Westbrook RH, et al
    When banding fails; investigation hails.
    Gut. 2017;66:322.
    PubMed    


    January 2017
  107. LEMOINE M, Thursz M, Mallet V, Shimakawa Y, et al
    Diagnostic accuracy of the gamma-glutamyl transpeptidase to platelet ratio (GPR) using transient elastography as a reference.
    Gut. 2017;66:195-196.
    PubMed    


    September 2016
  108. KUTTKAT N, Mohs A, Ohl K, Hooiveld G, et al
    Hepatic overexpression of cAMP-responsive element modulator alpha induces a regulatory T-cell response in a murine model of chronic liver disease.
    Gut. 2016 Sep 29. pii: gutjnl-2015-311119. doi: 10.1136/gutjnl-2015-311119.
    PubMed     Abstract available


  109. DAHEIM M, Lang S, Goeser T, Steffen HM, et al
    Real-world risk score for hepatocellular carcinoma risk prediction in CHBV: a validation outside of Asia.
    Gut. 2016 Sep 26. pii: gutjnl-2016-312993. doi: 10.1136/gutjnl-2016-312993.
    PubMed    


    August 2016
  110. HE GW, Gunther C, Kremer AE, Thonn V, et al
    PGAM5-mediated programmed necrosis of hepatocytes drives acute liver injury.
    Gut. 2016 Aug 26. pii: gutjnl-2015-311247. doi: 10.1136/gutjnl-2015-311247.
    PubMed     Abstract available


    July 2016
  111. JENDREK ST, Gotthardt D, Nitzsche T, Widmann L, et al
    Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
    Gut. 2016 Jul 12. pii: gutjnl-2016-311739. doi: 10.1136/gutjnl-2016-311739.
    PubMed     Abstract available


    February 2016
  112. JAMIL KM, Hydes TJ, Cheent KS, Cassidy SA, et al
    STAT4-associated natural killer cell tolerance following liver transplantation.
    Gut. 2016 Feb 17. pii: gutjnl-2015-309395. doi: 10.1136/gutjnl-2015-309395.
    PubMed     Abstract available


  113. WIESER V, Adolph TE, Enrich B, Kuliopulos A, et al
    Reversal of murine alcoholic steatohepatitis by pepducin-based functional blockade of interleukin-8 receptors.
    Gut. 2016 Feb 8. pii: gutjnl-2015-310344. doi: 10.1136/gutjnl-2015-310344.
    PubMed     Abstract available


    October 2015
  114. NAHON P, Lescat M, Layese R, Bourcier V, et al
    Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort).
    Gut. 2015 Oct 28. pii: gutjnl-2015-310275. doi: 10.1136/gutjnl-2015-310275.
    PubMed     Abstract available


    July 2015
  115. KENG CT, Sze CW, Zheng D, Zheng Z, et al
    Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection.
    Gut. 2015 Jul 6. pii: gutjnl-2014-307856. doi: 10.1136/gutjnl-2014-307856.
    PubMed     Abstract available


    June 2015
  116. LEMOINE M, Shimakawa Y, Nayagam S, Khalil M, et al
    The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa.
    Gut. 2015 Jun 24. pii: gutjnl-2015-309260. doi: 10.1136/gutjnl-2015-309260.
    PubMed     Abstract available


  117. ZHANG DY, Goossens N, Guo J, Tsai MC, et al
    A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection.
    Gut. 2015 Jun 4. pii: gutjnl-2015-309655. doi: 10.1136/gutjnl-2015-309655.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: